Erasca (ERAS) Short-term Investments (2020 - 2026)
Erasca posted quarterly Short-term Investments of $196.5 million for Q1 2026, down 16.05% year-on-year from $234.1 million in Q1 2025, and down 2.84% on a QoQ basis from $202.3 million in Q4 2025.
Erasca (ERAS) has 7 years of Short-term Investments data on file, last reported at $196.5 million in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments fell 16.05% year-over-year to $196.5 million; the trailing twelve-month figure through Mar 2026 stood at $196.5 million (down 16.05% YoY), and the FY2025 full-year result was $202.3 million, down 12.27% from the prior year.
- Short-term Investments for Q1 2026 stood at $196.5 million, down from $202.3 million in the prior quarter.
- Across five years, Short-term Investments topped out at $250.0 million in Q3 2024 and bottomed at $59.2 million in Q1 2022.
- The 5-year median for Short-term Investments is $202.3 million (2025), against an average of $184.8 million.
- The widest annual swing landed in 2022, when Short-term Investments surged 234.69%; it then dropped 16.05% in 2026.
- A 5-year view of Short-term Investments shows it stood at $151.4 million in 2022, then soared by 44.83% to $219.3 million in 2023, then climbed by 5.15% to $230.6 million in 2024, then slipped by 12.27% to $202.3 million in 2025, then declined by 2.84% to $196.5 million in 2026.
- The last three Short-term Investments figures came in at $196.5 million (Q1 2026), $202.3 million (Q4 2025), and $218.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196.53 Mn |
| Dec 31, 2025 | 202.27 Mn |
| Sep 30, 2025 | 218.17 Mn |
| Jun 30, 2025 | 234.52 Mn |
| Mar 31, 2025 | 234.10 Mn |
| Dec 31, 2024 | 230.57 Mn |
| Sep 30, 2024 | 250.03 Mn |
| Jun 30, 2024 | 235.61 Mn |
| Mar 31, 2024 | 220.96 Mn |
| Dec 31, 2023 | 219.28 Mn |
| Sep 30, 2023 | 183.81 Mn |
| Jun 30, 2023 | 178.46 Mn |
| Mar 31, 2023 | 116.99 Mn |
| Dec 31, 2022 | 151.40 Mn |
| Sep 30, 2022 | 136.67 Mn |
| Jun 30, 2022 | 73.47 Mn |
| Mar 31, 2022 | 59.19 Mn |
| Dec 31, 2021 | 53.99 Mn |
| Sep 30, 2021 | 40.83 Mn |
| Jun 30, 2021 | 37.28 Mn |
| Dec 31, 2020 | 53.33 Mn |